OncoMatch

OncoMatch/Clinical Trials/NCT07626736

Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC

Is NCT07626736 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for nonsmall cell lung cancer.

NARecruitingWen-zhao ZHONGNCT07626736Data as of Jul 2026Location: China

The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC). The main questions it aims to answer : What is the level of agreement between treatment recommendations generated by the AI model and those made by a traditional MDT? How often do clinicians modify their final treatment decision after reviewing the AI model's recommendation? Researchers will compare treatment plans from the traditional MDT (Arm 1), the AI model (Arm 2), and the clinician's final decision after reviewing the AI output (Arm 3) to assess consistency, decision modification rates, and clinical efficiency. Participants will: Have their clinical, imaging, and molecular data submitted to both the traditional MDT and the AI model for independent treatment recommendations Receive a final treatment plan determined by clinicians after reviewing both recommendations, with follow-up for safety and survival outcomes

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Excluded: Stage I

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07626736 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify